Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $7.1226 under a pre-arranged 10b5-1 trading plan.

Summary

• On August 20, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $7.1226, with individual trades ranging from $6.99 to $7.31.
• Following the transaction, Borgeson directly owns 7,132,769 shares of Recursion Pharmaceuticals' Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is part of a pre-planned trading strategy and doesn't necessarily reflect a change in the director's confidence in the company.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales in the context of the overall health and prospects of the company.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates